Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL-17A (LY3509754): A Phase I Randomized Placebo-Controlled Study

In conclusion, despite strong target engagement and a PK profile that supported once-daily administration, this study showed that oral dosing with LY3509754 was poorly tolerated.PMID:38294091 | DOI:10.1002/cpt.3185

Source: Clinical Pharmacology and Therapeutics - January 31, 2024 Category: Drugs & Pharmacology Authors: Amita Datta-Mannan Arie Regev David E Coutant Andrew J Dropsey Joanne Foster Spencer Jones Josh Poorbaugh Carsten Schmitz Evan Wang Michael E Woodman Source Type: research